Access Pharmaceuticals, Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Access Pharmaceuticals, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Access Pharmaceuticals, Inc.. The Group's principal activity is to develop drug delivery systems and advanced polymer technology for application in cancer treatment, dermatology and treatment of oral diseases. It is in the development stage. The Group has proprietary patents and rights to seven drug delivery technology platforms: synthetic polymer targeted delivery, vitamin mediated targeted delivery (including oral), bioerodible hydrogel technology, nanoparticles and nanoparticle networks, Residerm (R) topical delivery, carbohydrate targeting technology and agents for the prevention and treatment of viral disease, including HIV. The products Residerm (R) A gel - Zindaclin (TM), Aphthasol (R) and Aptheal (R) are being marketed currently. On 25-February-2009, the Group acquired MacroChem Corporation.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report